Look up one drug

PMS-Sulfasalazine-E.C. · DIN 00598488 Manufacturer: Pharmascience Inc.; listing date 1996-10-01 Health Canada: Marketed since 1984-12-31 · brand PMS-SULFASALAZINE-E.C. TAB 500MG · ATC A07EC01 SULFASALAZINE · form Tablet (enteric-coated) · route Oral · ingredients SULFASALAZINE 500 MG · company Pharmascience inc · schedule Prescription

DIN 00598488: PMS-Sulfasalazine-E.C. Raw flags: sec3=Y Item: 082400006; group id 122; item number 0205; lccId None; manufacturer id PMS Source form: Ent Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.3863; ministry $0.3863 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00598488 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5864

Interchangeable products

Salazopyrin EN-TABS 500 MG · DIN 02064472 · $0.3863

Shortage status: resolved shortage (ended 2022-10-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00598488

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Salazopyrin EN-TABS 500 MG · DIN 02064472 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2009-02-03 · brand SALAZOPYRIN EN-TABS 500 MG · ATC A07EC01 SULFASALAZINE · form Tablet (enteric-coated) · route Oral · ingredients SULFASALAZINE 500 MG · company Pfizer canada ulc · schedule Prescription

DIN 02064472: Salazopyrin EN-TABS 500 MG Raw flags: sec3=Y Item: 082400006; group id 122; item number 0205; lccId None; manufacturer id PFI Source form: Ent Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.5616; ministry $0.3863 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02064472 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17417

Interchangeable products

PMS-Sulfasalazine-E.C. · DIN 00598488 · $0.3863

Shortage status: resolved shortage (ended 2023-04-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02064472

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Jamp Sulfasalazine · DIN 02544652 Manufacturer: Jamp Pharma Corporation; listing date 2026-02-27 Health Canada: Marketed since 2025-12-10 · brand JAMP SULFASALAZINE · ATC A07EC01 SULFASALAZINE · form Tablet · route Oral · ingredients SULFASALAZINE 500 MG · company Jamp pharma corporation · schedule Prescription

DIN 02544652: Jamp Sulfasalazine Raw flags: sec3=Y Item: 082400005; group id 122; item number 0206; lccId None; manufacturer id JPC Source form: Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.1807; ministry $0.1807 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02544652 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103322

Interchangeable products

PMS-Sulfasalazine · DIN 00598461 · $0.1807 Salazopyrin · DIN 02064480 · $0.1807

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02544652

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

PMS-Sulfasalazine · DIN 00598461 Manufacturer: Pharmascience Inc.; listing date 1996-10-01 Health Canada: Marketed since 1984-12-31 · brand PMS-SULFASALAZINE 500MG/TAB USP · ATC A07EC01 SULFASALAZINE · form Tablet · route Oral · ingredients SULFASALAZINE 500 MG · company Pharmascience inc · schedule Prescription

DIN 00598461: PMS-Sulfasalazine Raw flags: sec3=Y Item: 082400005; group id 122; item number 0206; lccId None; manufacturer id PMS Source form: Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.1807; ministry $0.1807 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00598461 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5728

Interchangeable products

Jamp Sulfasalazine · DIN 02544652 · $0.1807 Salazopyrin · DIN 02064480 · $0.1807

Shortage status: resolved shortage (ended 2022-05-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00598461

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Salazopyrin · DIN 02064480 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2006-01-11 · brand SALAZOPYRIN TAB 500MG · ATC A07EC01 SULFASALAZINE · form Tablet · route Oral · ingredients SULFASALAZINE 500 MG · company Pfizer canada ulc · schedule Prescription

DIN 02064480: Salazopyrin Raw flags: sec3=Y Item: 082400005; group id 122; item number 0206; lccId None; manufacturer id PFI Source form: Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.3682; ministry $0.1807 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02064480 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17416

Interchangeable products

Jamp Sulfasalazine · DIN 02544652 · $0.1807 PMS-Sulfasalazine · DIN 00598461 · $0.1807

Shortage status: resolved shortage (ended 2022-04-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02064480

Shortage record checked 2026-09-13T08:10:21.292534+00:00